Talking Rheumatology Research

Ep 20. Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in juvenile-onset IRDs

February 09, 2023 British Society for Rheumatology Season 1 Episode 20
Talking Rheumatology Research
Ep 20. Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in juvenile-onset IRDs
Show Notes

Effectiveness of the BNT162b2 mRNA COVID-19 vaccine among adolescents with juvenile-onset inflammatory rheumatic diseases (IRDs).

Dr Amit Ziv and Prof Yosef Uziel (both Tel Aviv University and Meir Medical Center, Israel) join Dr Herman Tam to discuss the effectiveness of the BNT162b2 mRNA COVID-19 vaccine in preventing infection in adolescents with juvenile-onset IRDs.

You can read this article in Rheumatology.

Thanks for listening to Talking Rheumatology Research! Join the conversation on Twitter using #TalkingRheumResearch, tweet us @RheumJnl, or find us on Instagram.

Want to read more rheumatology research? Explore Rheumatology and Rheumatology Advances in Practice.